The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
BackgroundThe association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison with other disease states associated with potential cytokine storm (CS) such as Staphylococcus aureus bacteraemia (SAB) are ill-defined.MethodsA cohort of 55 hospitalized SARS-CoV-2 positive patients was prospectively recruited – blood sampling was performed at baseline, post-treatment and hospital discharge. Serum IL-6, C-reactive protein (CRP) and other laboratory investigations were compared between treatment groups and across timepoints. Acute serum IL-6 and CRP levels were then compared to those with suspected COVID-19 (SCOVID) and age and sex matched patients with SAB and patients hospitalized for any non-infectious condition (NIC).ResultsIL-6 was elevated at admission in the SARS-CoV-2 cohort but at lower levels compared to matched SAB patients. Median (IQR) IL-6 at admission was 73.89 pg/mL (30.9, 126.39) in SARS-CoV-2 compared to 92.76 pg/mL (21.75, 246.55) in SAB (p=0.017); 12.50 pg/mL (3.06, 35.77) in patients with NIC; and 95.51 pg/mL (52.17, 756.67) in SCOVID. Median IL-6 and CRP levels decreased between admission and discharge timepoints. This reduction was amplified in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity.ConclusionsKnowledge of the kinetics of IL-6 did not offer enhanced predictive value for disease severity in COVID-19 over common investigations such as CRP and vital signs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in Immunology - 12(2021) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ana Copaescu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
C-reactive protein |
|---|
| doi: |
10.3389/fimmu.2021.646095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ053213416 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ053213416 | ||
| 003 | DE-627 | ||
| 005 | 20230308172941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2021.646095 |2 doi | |
| 035 | |a (DE-627)DOAJ053213416 | ||
| 035 | |a (DE-599)DOAJ5094b808a226498fb602653e7bd9938c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Ana Copaescu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a BackgroundThe association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison with other disease states associated with potential cytokine storm (CS) such as Staphylococcus aureus bacteraemia (SAB) are ill-defined.MethodsA cohort of 55 hospitalized SARS-CoV-2 positive patients was prospectively recruited – blood sampling was performed at baseline, post-treatment and hospital discharge. Serum IL-6, C-reactive protein (CRP) and other laboratory investigations were compared between treatment groups and across timepoints. Acute serum IL-6 and CRP levels were then compared to those with suspected COVID-19 (SCOVID) and age and sex matched patients with SAB and patients hospitalized for any non-infectious condition (NIC).ResultsIL-6 was elevated at admission in the SARS-CoV-2 cohort but at lower levels compared to matched SAB patients. Median (IQR) IL-6 at admission was 73.89 pg/mL (30.9, 126.39) in SARS-CoV-2 compared to 92.76 pg/mL (21.75, 246.55) in SAB (p=0.017); 12.50 pg/mL (3.06, 35.77) in patients with NIC; and 95.51 pg/mL (52.17, 756.67) in SCOVID. Median IL-6 and CRP levels decreased between admission and discharge timepoints. This reduction was amplified in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity.ConclusionsKnowledge of the kinetics of IL-6 did not offer enhanced predictive value for disease severity in COVID-19 over common investigations such as CRP and vital signs. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a interleukin-6 | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a Staphylococcus aureus bacteraemia | |
| 650 | 4 | |a sepsis | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Ana Copaescu |e verfasserin |4 aut | |
| 700 | 0 | |a Ana Copaescu |e verfasserin |4 aut | |
| 700 | 0 | |a Fiona James |e verfasserin |4 aut | |
| 700 | 0 | |a Effie Mouhtouris |e verfasserin |4 aut | |
| 700 | 0 | |a Sara Vogrin |e verfasserin |4 aut | |
| 700 | 0 | |a Olivia C. Smibert |e verfasserin |4 aut | |
| 700 | 0 | |a Claire L. Gordon |e verfasserin |4 aut | |
| 700 | 0 | |a Claire L. Gordon |e verfasserin |4 aut | |
| 700 | 0 | |a George Drewett |e verfasserin |4 aut | |
| 700 | 0 | |a Natasha E. Holmes |e verfasserin |4 aut | |
| 700 | 0 | |a Natasha E. Holmes |e verfasserin |4 aut | |
| 700 | 0 | |a Natasha E. Holmes |e verfasserin |4 aut | |
| 700 | 0 | |a Jason A. Trubiano |e verfasserin |4 aut | |
| 700 | 0 | |a Jason A. Trubiano |e verfasserin |4 aut | |
| 700 | 0 | |a Jason A. Trubiano |e verfasserin |4 aut | |
| 700 | 0 | |a Jason A. Trubiano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Immunology |d Frontiers Media S.A., 2011 |g 12(2021) |w (DE-627)DOAJ000031690 |x 16643224 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2021.646095 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/5094b808a226498fb602653e7bd9938c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2021.646095/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-3224 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 | ||